Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $189,420.00 in Stock

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, October 20th. The shares were sold at an average price of $13.53, for a total value of $189,420.00. Following the completion of the sale, the chief financial officer owned 69,828 shares of the company’s stock, valued at approximately $944,772.84. This represents a 16.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dominic Piscitelli also recently made the following trade(s):

• On Monday, September 28th, Dominic Piscitelli sold 13,400 shares of Oric Pharmaceuticals stock. The shares were sold at an average price of $13.53, for a total value of $181,302.00.
• On Thursday, September 24th, Dominic Piscitelli sold 600 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $13.50, for a total value of $8,100.00.
• On Wednesday, August 26th, Dominic Piscitelli sold 77,000 shares of Oric Pharmaceuticals stock. The stock was sold at an average price of $13.69, for a total value of $1,054,130.00.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ:ORIC opened at $13.17 on Friday. Oric Pharmaceuticals, Inc. has a 52-week low of $7.23 and a 52-week high of $14.68. The business’s 50 day simple moving average is $12.93 and its two-hundred day simple moving average is $11.03. The firm has a market cap of $1.37 billion, a P/E ratio of -9.76 and a beta of 0.99.

Oric Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, August 3rd. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.02). On average, equities analysts forecast that Oric Pharmaceuticals, Inc. will post -1.53 earnings per share for the current fiscal year.

Key Stories Impacting Oric Pharmaceuticals

Here are the key news stories impacting Oric Pharmaceuticals this week:

• Positive Sentiment: Promising enozertinib efficacy: At the ESMO Congress 2026, Oric reported an 84% confirmed systemic objective response rate and a 70% confirmed intracranial response rate in first-line non-small-cell lung cancer patients with EGFR atypical mutations. The data included multiple complete responses in the brain, an important potential advantage in a patient population with substantial baseline CNS metastases. Oric enozertinib ESMO data and Phase 3 announcement
• Positive Sentiment: Phase 3 development planned: Oric plans to advance enozertinib into the global Redwood-1 Phase 3 trial in the first half of 2027. Moving into a registrational study could increase the program’s commercial potential and represents a meaningful development milestone for investors. ORIC plans Phase 3 trial after lung cancer data
• Positive Sentiment: Additional pipeline support: Preclinical and translational findings suggest rinzimetostat may help restore sensitivity to androgen-receptor inhibition in prostate cancer and may retain activity against resistance mutations that can undermine EZH2 inhibitors. These findings are earlier-stage but broaden the potential value of Oric’s pipeline. Oric rinzimetostat prostate cancer data
• Neutral Sentiment: Analyst expectations remain favorable: Oric has a consensus “Moderate Buy” rating and an average price target of $21.17, although analyst opinions are not a substitute for clinical or regulatory success.
• Negative Sentiment: CFO insider selling: CFO Dominic Piscitelli sold 14,000 shares worth approximately $189,420 under a pre-arranged Rule 10b5-1 trading plan. The sale reduced his holdings by 16.7%; while planned transactions may be routine, insider selling can weigh on sentiment.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Quantinno Capital Management LP grew its stake in shares of Oric Pharmaceuticals by 9.3% in the 1st quarter. Quantinno Capital Management LP now owns 25,526 shares of the company’s stock worth $323,000 after acquiring an additional 2,170 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Oric Pharmaceuticals by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 190,470 shares of the company’s stock valued at $2,413,000 after purchasing an additional 2,549 shares during the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Oric Pharmaceuticals in the second quarter valued at about $38,000. Quantbot Technologies LP purchased a new stake in shares of Oric Pharmaceuticals in the second quarter valued at about $46,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Oric Pharmaceuticals by 17.0% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,470 shares of the company’s stock valued at $687,000 after purchasing an additional 9,231 shares in the last quarter. Institutional investors own 95.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on ORIC shares. BTIG Research started coverage on shares of Oric Pharmaceuticals in a research note on Wednesday, September 23rd. They set a “buy” rating and a $26.00 price target for the company. JPMorgan Chase & Co. raised their price objective on shares of Oric Pharmaceuticals from $23.00 to $26.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. HC Wainwright raised their price objective on shares of Oric Pharmaceuticals from $25.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Thursday, October 15th. Finally, Wall Street Zen raised shares of Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, July 25th. Fourteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Oric Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $21.17.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc (NASDAQ: ORIC) is a clinical-stage biopharmaceutical company focused on developing medicines that overcome mechanisms of treatment resistance in cancer. The company uses its discovery platform to identify therapies intended to improve or restore the effectiveness of existing cancer treatments.

Oric’s pipeline has included ORIC-533, an oral small-molecule inhibitor of CD73 designed to block adenosine-mediated immunosuppression in the tumor microenvironment. The company has evaluated the program in hematologic malignancies, including multiple myeloma.